We describe a versatile and quick route to cationic gold(I) complexes containing N-heterocyclic carbenes and a second ancillary ligand (such as phosphanes, phosphites, arsines and amines) of interest for the synthesis of compounds with potential catalytic and medicinal applications. The general synthetic strategy has been applied to the preparation of novel cationic heterobimetallic ruthenium(II)-gold(I) complexes that are highly cytotoxic on renal cancer Caki-1 and colon cancer HCT 116 cell lines while showing a synergistic effect and being more selective than their monometallic counterparts.
The chemistry of gold(I) complexes containing N-heterocyclic carbenes 1 has developed rapidly in the past decade with the findings of their relevant applications as homogeneous catalysts [1] [2] [3] [4] [5] [6] [7] and their potential as anticancer and antimicrobial agents [7] [8] [9] [10] [11] [12] [13] [14] (including some heterometallic complexes 15, 16 ). The beneficial effects of a second ligand in processes catalyzed by gold(I)-N-heterocyclic compounds have been described. 17 Cationic gold(I) N-heterocyclic carbene complexes containing phosphanes of the type [(NHC)AuPR 3 ]I (NHC = 1,3-diethylbenzimidazol-2-ylidene) have been described recently by Ott et al. as very efficient enzyme inhibitors with promising potential as anticancer chemotherapeutics. 18, 19 The preparation of these complexes involves the addition of NaCO 3 to the N-heterocyclic imidazolium iodide at 50 o C followed by addition the corresponding chlorido(phosphane) gold(I) derivatives with reactions times ranging from 8 to 60 hours, and subsequent purification by extraction in CH 2 20 We describe here a simple and efficient synthetic method to obtain gold(I)-N-heterocyclic carbenes with a second ancillary ligand by abstraction of the chloride with silver perchlorate in compounds [(NHC)AuCl] 21 and subsequent addition of the ancillary ligand (Scheme1, total reaction time 30 min). The reaction scheme is quite general and different phosphanes such as PPh 3 and PEt 3 can be used. We also synthesized cationic complexes containing NHC and a phosphite P(OEt 3 ) 3 , triphenylarsine AsPh 3 and bipyridine (bipy) as second ligand. 6 or AgX (24 h reaction). 21 For different synthetic/catalytic purposes it may be relevant to separate the AgCl formed in the abstraction reaction before addition of the second ancillary ligand. We have demonstrated that the use of a silver salt containing an anion that can be covalently coordinated to gold, allows for the separation of solutions (after filtration of AgCl) containing in situ generated [(NHC)AuOClO 3 ] species that are stable for at least 72h at 5 o C, and during 2 hours at RT. The covalent nature of the OClO 3 -group in the intermediate has been confirmed by IR spectroscopy (spectra and explanations in the ESI). The addition of different ancillary ligands to these solutions leads to immediate formation of stable cationic species (2-6) that precipitate in the reaction media in high yields and that can be separated by filtration without further purification (Scheme 1). The reaction can also be performed with silver triflate (AgOSO 2 CF 3 ) (2b). It should be noted that compound 4 is an stable precursor to the phosphane derivatives by displacement of the more labile AsPh 3 .
We have used this general synthetic method to incorporate a phosphane fragment containing a second metal center and generate new cationic heterobimetallic ruthenium-gold complexes. Our group has been involved in the preparation of heterometallic complexes containing gold(I) phosphane moeties as potential cancer chemotherapeutics. [23] [24] [25] [26] The hypothesis is that the incorporation of two active metals in the same molecule may improve their activity as anti-tumor agents due to interaction of the different metals with multiple biological targets (cooperative effect) or by the improved chemicophysical properties of the resulting heterometallic compound (synergism). We have prepared a number of titanocene-gold derivatives with high efficacy in ovarian and prostate cancer in vitro 23 and in renal cancer both in vitro 24 and in vivo 25 . We and others have also reported recently on the design of heterometallic ruthenium-gold complexes with relevant in vitro properties against HCT 116 colon cancer cell lines (7 and 8 in Chart 1). 26 We found in most cases a synergistic effect of the heterometallic compound when compared to its monometallic counterparts (either alone or in combination).
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Chart 1 Previous heterometallic Ru-Au complexes synthesized in our group. 26 We aimed to incorporate gold(I)-N-heterocyclic fragments to [Ru(p-cymene)Cl 2 (η 1 -dppm)] 9 species to improve the pharmacological profile of previously reported heterometallic complexes 7 and 8. Gold NHC complexes display strong antimitochondrial effects, which can be attributed to both their cationic and lipophilic characters. 27, 28 Single crystals of compounds 13 and 14 were isolated as bright orange needles in mixtures of dichloromethane/Et 2 O. The structure of 13 is depicted below along including selected angles and distances. The structure of 14 is collected in the ESI along with crystallographic data and tables of selected distances and angles for both 13 and 14 (quite similar). Coordination bond lengths and angles of the two metal ions in 13 and 14 (ESI) are in agreement with those found for similar complexes retrieved in a search in the CSD (v. 1.16) 26, 30 and in the structure of previously described [Ru(p-cymene)Cl 2 (μ-dppm)AuCl] (7). 26 The bond lengths Au(1)-P(2) and Au(1)-C (1) are respectively 2.228 (7) Table 1 (a complete Table including data on the DLD1 cell line and the combination of monometallic 9 and We studied the effect of the combination of monometallic gold 1, 10-12 and ruthenium 9 compounds (1:1 equivalents) in Caki-1 cell lines at 72 h which in all cases gave IC 50 values larger than those of the bimetallic compounds (ESI). This fact supports the idea that there is indeed a synergistic effect for the heterometallic complexes in their in vitro activity on the renal cancer cell line. We analyzed the interactions of 13-16 with representative DNA molecules. Specifically, we carried out gel electrophoresis studies to disclose the effects of the new heterobimetallic compounds on plasmid (pBR322) DNA (ESI). Compound [Ru(pcymene)Cl 2 (η 1 -dppm)] 9 weakly reduced supercoiling in plasmid DNA although it was able to bind DNA in a non-intercalative fashion. 31 Most Gold(I)-N-heterocyclic carbene complexes (unless designed to target DNA quadruplexes) are known to not interact or interact only weakly with DNA. 10 Treatment with increasing amounts of heterometallic RuAu derivatives 13-16 did not affect the mobility of the faster-running supercoiled form (Form I) even at the highest molar ratios (ESI). The lack of interaction between the heterobimetallic compounds and plasmid (pBR322) DNA (already observed for previously described [Ru(pcymene)Cl 2 (μ-dppm)AuX] compounds, X = Cl 7, thiazoline 8) points out that other biomolecular targets are probably implicated in the cell death pathway.
Changes in cell anti-oxidant capacity are a characteristic of many chemo-resistant cancers, and overexpression of thioredoxin reductase (TrRx) is among the key defense and survival mechanisms of cisplatin-resistant cells. We have reported on the inhibition of TrRx in Caki-1 cells by Auranofin and heterometallic titanocene-gold complexes. 25 Since Au-NHC compounds are known to inhibit TrRx, we measured the activity of thioredoxin reductase in Caki-1 cells, following incubation with compounds 13, 1 and 9. We found thioredoxin reductase activity to be lower in cells treated with 5 μM of 1, 9, 13, with an observed inhibition of 17%, 44% and 63% respectively after a 24 hour incubation (Figure 2 In conclusion, the general synthetic strategy described here may be used for the preparation of cationic gold(I)-Nheterocyclic carbene complexes containing a second neutral ligand. The mild reaction conditions and the complete separation of silver salts before the addition of the second ligand, has allowed for the preparation of novel heterometallic RuAu complexes that have resulted highly active in vitro against renal and colon cancer cell lines while being more selective and active than the monometallic counterparts (either alone or in combination). The biological activity of these new derivatives is currently being further explored.
We envision that the versatility of this method will enable the synthesis of a broad range of compounds (e.g. multimetallic systems, polymers, nanocarriers) for which the incorporation of [Au(NHC)] species may improve their biological or catalytic applications.
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